Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $95.16 million. The enterprise value is $63.80 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 188.84 million shares outstanding. The number of shares has increased by 7.29% in one year.
| Current Share Class | 188.84M |
| Shares Outstanding | 188.84M |
| Shares Change (YoY) | +7.29% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 28.68% |
| Float | 145.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.63 |
| Forward PS | 8.61 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 10.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.48 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.50% and return on invested capital (ROIC) is -17.48%.
| Return on Equity (ROE) | -30.50% |
| Return on Assets (ROA) | -11.84% |
| Return on Capital (ROIC) | -17.48% |
| Revenue Per Employee | $116,253 |
| Profits Per Employee | -$268,147 |
| Employee Count | 75 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.52% in the last 52 weeks. The beta is 1.28, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -47.52% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 22.51 |
| Average Volume (20 Days) | 1,861,777 |
Short Selling Information
The latest short interest is 15.94 million, so 8.44% of the outstanding shares have been sold short.
| Short Interest | 15.94M |
| Short Previous Month | 15.22M |
| Short % of Shares Out | 8.44% |
| Short % of Float | 10.92% |
| Short Ratio (days to cover) | 35.21 |
Income Statement
In the last 12 months, LCTX had revenue of $8.72 million and -$20.11 million in losses. Loss per share was -$0.11.
| Revenue | 8.72M |
| Gross Profit | 11.03M |
| Operating Income | -19.20M |
| Pretax Income | -24.19M |
| Net Income | -20.11M |
| EBITDA | -18.57M |
| EBIT | -19.20M |
| Loss Per Share | -$0.11 |
Full Income StatementBalance Sheet
The company has $32.71 million in cash and $2.75 million in debt, giving a net cash position of $29.96 million or $0.16 per share.
| Cash & Cash Equivalents | 32.71M |
| Total Debt | 2.75M |
| Net Cash | 29.96M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 64.79M |
| Book Value Per Share | 0.35 |
| Working Capital | 20.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.77 million and capital expenditures -$291,000, giving a free cash flow of -$23.06 million.
| Operating Cash Flow | -22.77M |
| Capital Expenditures | -291,000 |
| Free Cash Flow | -23.06M |
| FCF Per Share | -$0.12 |
Full Cash Flow StatementMargins
Gross margin is 126.54%, with operating and profit margins of -220.21% and -230.66%.
| Gross Margin | 126.54% |
| Operating Margin | -220.21% |
| Pretax Margin | -229.91% |
| Profit Margin | -230.66% |
| EBITDA Margin | -212.95% |
| EBIT Margin | -220.21% |
| FCF Margin | -361.02% |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.29% |
| Shareholder Yield | -7.29% |
| Earnings Yield | -21.13% |
| FCF Yield | -24.23% |
Dividend DetailsAnalyst Forecast
The average price target for LCTX is $4.75, which is 842.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.75 |
| Price Target Difference | 842.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 76.94% |
| EPS Growth Forecast (5Y) | 1.28% |
Stock ForecastsStock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -2.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.42 |
| Piotroski F-Score | 2 |